Isotretinoin

Summary

Isotretinoin (CHEMBL547) is an approved small-molecule keratolytic drug (ATC D10BA01); indicated across 51 conditions including acne and neuroblastoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D10BA01 (+2 more)
• Indications: 51 conditions
• Clinical trials: 137
• Chemistry: 300.4 Da · C20H28O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL547
Name	Isotretinoin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5282379
ChEBI	CHEBI:6067
ATC	D10BA01, D10AD54, D10AD04
Molecular formula	C20H28O2
Molecular weight	300.4
InChIKey	SHGAZHPCJJPHSC-XFYACQKRSA-N

SMILES: CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\C(=O)O)/C)/C

IUPAC name: (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid

ChEBI definition: A retinoic acid that is all-trans-retinoic acid in which the double bond which is α,β- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.

Pharmacological roles (ChEBI): keratolytic drug, antineoplastic agent, teratogenic agent.

Also known as: 13 cis-retinoic acid, Absorica, Absorica ld, Accutane, Amnesteem, Claravis, Isotretinoin, Isotretinoina, Isotretinoine, Isotrex, Myorisan, NSC-758156

Patent coverage: 8,634 distinct patent families (31,016 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 17 (assay-derived). Sample: Microtubule-associated protein tau, RecQ-like DNA helicase BLM, Ferritin light chain, Peripheral myelin protein 22, 5-hydroxytryptamine receptor 2B, Alpha-2B adrenergic receptor, Thyroid hormone receptor beta, Prostaglandin G/H synthase 1, Adenosine receptor A3, Mitogen-activated protein kinase 14, Serine/threonine-protein kinase mTOR, Cruzipain, Aldehyde dehydrogenase 1A1, Mitogen-activated protein kinase 1, Olfactory receptor 51E2, Cellular retinoic acid-binding protein 1, Bile salt export pump.

Bioactivity

ChEMBL activities: 14 potent at pChembl ≥ 5 of 27 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
OR51E2	6.8	IC50	160	nM	CHEMBL_ACT_19491341
MAPK1	6.33	IC50	462	nM	CHEMBL_ACT_7750438
HTR2B	6.27	Ki	540	nM	CHEMBL_ACT_7750463
HTR2B	6.07	IC50	848	nM	CHEMBL_ACT_7750462
P40220	6.05	IC50	900	nM	CHEMBL_ACT_230760
P40220	6.05	IC50	900	nM	CHEMBL_ACT_875651
ADORA3	5.63	Ki	2357	nM	CHEMBL_ACT_7780332
PMP22	5.62	Potency	2393	nM	CHEMBL_ACT_4358326
MAPK14	5.6	IC50	2529	nM	CHEMBL_ACT_7750440
ADRA2B	5.52	Ki	3019	nM	CHEMBL_ACT_7780344
ADORA3	5.38	IC50	4169	nM	CHEMBL_ACT_7780331
MTOR	5.33	Potency	4645	nM	CHEMBL_ACT_4522703
PTGS1	5.3	AC50	4968	nM	CHEMBL_ACT_25205281
ADRA2B	5.18	IC50	6612	nM	CHEMBL_ACT_7780343

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
acne	4	MONDO:0011438	EFO:0003894

43 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
neuroblastoma	3	MONDO:0005072	EFO:0000621
rosacea	3	MONDO:0006604	EFO:1000760
medulloblastoma	3	MONDO:0007959	EFO:0002939
head and neck cancer	3	MONDO:0005627	EFO:0006859
ganglioneuroblastoma	3	MONDO:0005035	EFO:0000502
brain neoplasm	3	MONDO:0021211	EFO:0003833
central nervous system neoplasm	3	MONDO:0006130	EFO:1000158
dysplasia of cervix	3	MONDO:0006736	EFO:1000910
kidney cancer	3	MONDO:0002367	MONDO:0002367
lung neoplasm	3	MONDO:0021117	MONDO:0008903
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
breast neoplasm	3	MONDO:0021100	MONDO:0007254
actinic keratosis	2	MONDO:0005173	EFO:0002496
HIV infectious disease	2	MONDO:0005109	EFO:0000180
glioblastoma	2	MONDO:0018177	EFO:0000519
leukemia	2	MONDO:0005059	EFO:0000565
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
focal segmental glomerulosclerosis	2	MONDO:0100313	EFO:0004236
juvenile myelomonocytic leukemia	2	MONDO:0011908	EFO:1000309
mycosis fungoides	2	MONDO:0009691	EFO:1001051
tinea pedis	2	MONDO:0005984	EFO:0007512
spermatogenic failure	2	MONDO:0004983	EFO:0000279
pulmonary emphysema	2	MONDO:0004849	EFO:0000464
Klinefelter syndrome	2	MONDO:0006823	EFO:1001006
ichthyosis	2	MONDO:0019269	MONDO:0019269
lymphoma	2	MONDO:0005062	EFO:0000574
Hodgkins lymphoma	1	MONDO:0004952	EFO:0000183
myelodysplastic syndrome	1	MONDO:0018881	EFO:0000198
acute myeloid leukemia	1	MONDO:0018874	EFO:0000222
acute promyelocytic leukemia	1	MONDO:0012883	EFO:0000224
Burkitt lymphoma	1	MONDO:0007243	EFO:0000309
chronic myeloid leukemia	1	MONDO:0011996	EFO:0000339
diffuse large B-cell lymphoma	1	MONDO:0018905	EFO:0000403
neoplasm	1	MONDO:0005070	EFO:0000616
renal cell carcinoma	1	MONDO:0005086	EFO:0000681
anaplastic astrocytoma	1	MONDO:0016684	EFO:0002499
anaplastic oligodendroglioma	1	MONDO:0016696	EFO:0002501
epidermolysis bullosa	1	MONDO:0006541	EFO:1000690
gliosarcoma	1	MONDO:0016681	EFO:1001465
glioma	1	MONDO:0021042	MONDO:0003268
Alzheimer disease	1	MONDO:0004975	MONDO:0004975
Wilms tumor	1	MONDO:0006058	MONDO:0006058
oligodendroglioma	1	MONDO:0016695	MONDO:0002543

7 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 137.

Phase distribution

Phase	Trials
PHASE2	41
PHASE3	25
PHASE1	25
Not specified	21
PHASE4	14
PHASE1/PHASE2	8
EARLY_PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06698263	PHASE4	NOT_YET_RECRUITING	13-cis Retinoic Acid (Isotretinoin) and Sperm Production
NCT01139749	PHASE4	UNKNOWN	Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea
NCT01404130	PHASE4	COMPLETED	A Pilot Study of the Effects of Isotretinoin on Cognition, Learning and Memory
NCT01445028	PHASE4	COMPLETED	Isotretinoin for Proliferative Vitreoretinopathy
NCT02457520	PHASE4	COMPLETED	ABSORICA in Patients With Severe Recalcitrant Nodular Acne
NCT02855138	PHASE4	COMPLETED	Effects of Isotretinoin on The Gonads and Hirsutism
NCT03076021	PHASE4	COMPLETED	Effects of Isotretinoin on CYP2D6 Activity
NCT04940767	PHASE4	COMPLETED	A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris
NCT05218486	PHASE4	UNKNOWN	Effect of Oral Isotretinoin on The Level of SerumYKL40 in Acne Vulgaris Patients
NCT05316675	PHASE4	UNKNOWN	Impact of Isotretinoin in Different Doses on Quality of Life
NCT05529888	PHASE4	COMPLETED	Measure the Serum Level of Homocysteine in Acne Patients Before and After Oral Isotretinoin.
NCT05666765	PHASE4	UNKNOWN	Comparison Between Isotretinoin, Silymarin and Both in the Treatment of Acne Vulgaris
NCT06873087	PHASE4	COMPLETED	Changes in PACAP, CGRP, and VIP Levels in Rosacea Patients on Systemic Isotretinoin and Their Association with Erythema
NCT07228481	PHASE4	COMPLETED	Study of Two Dosages of Roaccutane in Cystic Acne
NCT00392327	PHASE3	ACTIVE_NOT_RECRUITING	Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
NCT03126916	PHASE3	RECRUITING	Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NCT06172296	PHASE3	RECRUITING	Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06447480	PHASE3	RECRUITING	Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients
NCT00001073	PHASE3	COMPLETED	Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors
NCT00002737	PHASE3	COMPLETED	Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer
NCT00003564	PHASE3	WITHDRAWN	Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas
NCT00003599	PHASE3	WITHDRAWN	Vitamin E in Preventing the Side Effects of Isotretinoin in Former and Current Smokers Who Are Receiving Isotretinoin to Prevent Lung Cancer
NCT00004188	PHASE3	COMPLETED	Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
NCT00026312	PHASE3	COMPLETED	Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
NCT00030719	PHASE3	UNKNOWN	Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
NCT00054561	PHASE3	COMPLETED	Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00078988	PHASE3	COMPLETED	High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas
NCT00410631	PHASE3	UNKNOWN	Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma
NCT00499616	PHASE3	COMPLETED	Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
NCT00567567	PHASE3	COMPLETED	Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
NCT00882531	PHASE3	COMPLETED	Isotretinoin in Papular-Pustular Rosacea
NCT00975143	PHASE3	COMPLETED	Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
NCT01041638	PHASE3	COMPLETED	Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma
NCT01474590	PHASE3	COMPLETED	Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne
NCT03370367	PHASE3	COMPLETED	Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer
NCT04290572	PHASE3	UNKNOWN	Efficacy and Safety of Oral Isotretinoin for the Treatment of Facial Recalcitrant Flat Warts
NCT04353180	PHASE3	UNKNOWN	Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)
NCT06242288	PHASE3	COMPLETED	Correlation Between Depression Scores and Serum NF-ĸB/NLRP3 Axis, Biotinidase, and HMGB After Treatment With Isotretinoin in Patients With Acne Vulgaris
NCT06451237	PHASE3	COMPLETED	Acne Remission Maintenance by Weekend Systemic Isotretinoin
NCT03786783	PHASE2	ACTIVE_NOT_RECRUITING	Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
NCT04385277	PHASE2	ACTIVE_NOT_RECRUITING	Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
NCT07481370	PHASE2	ENROLLING_BY_INVITATION	Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm
NCT00002506	PHASE2	COMPLETED	Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer
NCT00002586	PHASE2	COMPLETED	13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer
NCT00003405	PHASE2	WITHDRAWN	Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
NCT00003585	PHASE1/PHASE2	COMPLETED	Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
NCT00003619	PHASE1/PHASE2	COMPLETED	Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
NCT00004110	PHASE2	COMPLETED	Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma
NCT00005847	PHASE2	COMPLETED	Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00017368	PHASE2	COMPLETED	Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma
NCT00021359	PHASE2	COMPLETED	Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma
NCT00025038	PHASE2	COMPLETED	Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia
NCT00038376	PHASE2	COMPLETED	Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
NCT00040872	PHASE2	COMPLETED	Multiple Therapies in Treating Patients With Advanced Neuroblastoma
NCT00062010	PHASE2	COMPLETED	Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
NCT00089258	PHASE2	COMPLETED	Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment
NCT00098020	PHASE2	COMPLETED	Podocyte Retinoids
NCT00112502	PHASE2	COMPLETED	Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
NCT00135135	PHASE2	COMPLETED	Therapy for Children With Neuroblastoma
NCT00138151	PHASE2	TERMINATED	Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer
NCT00176527	PHASE2	TERMINATED	Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00324740	PHASE1/PHASE2	TERMINATED	Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
NCT00528437	PHASE2	COMPLETED	Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NCT00555399	PHASE1/PHASE2	TERMINATED	Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
NCT00701740	PHASE2	COMPLETED	Oral Isotretinoin for Photoaging: Results of a Randomized Controlled Phase II Trial
NCT00808899	PHASE2	TERMINATED	Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
NCT00842907	PHASE2	UNKNOWN	Efficacy and Safety of Oral Isotretinoin for Cutaneous Photodamage
NCT00969722	PHASE2	TERMINATED	A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients
NCT01183416	PHASE2	COMPLETED	High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
NCT01183429	PHASE2	COMPLETED	3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
NCT01334515	PHASE2	COMPLETED	Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
NCT01560585	PHASE1/PHASE2	TERMINATED	Open Label Study of Isotretinoin in Mild to Moderate Alzheimer’s Disease
NCT01592045	PHASE1/PHASE2	COMPLETED	ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
NCT01701479	PHASE1/PHASE2	UNKNOWN	Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
NCT01857934	PHASE2	COMPLETED	Therapy for Children With Advanced Stage Neuroblastoma
NCT01969058	PHASE2	COMPLETED	Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery
NCT02061384	PHASE2	COMPLETED	RA-2 13-cis Retinoic Acid (Isotretinoin)
NCT02278861	PHASE2	COMPLETED	Oral Isotretinoin Versus Topical Tretinoin for Actinic Keratosis
NCT02771743	PHASE2	UNKNOWN	Response-based Treatment of High-risk Neuroblastoma
NCT02864082	PHASE2	COMPLETED	A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
NCT03033303	PHASE2	COMPLETED	A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
NCT03323801	PHASE2	COMPLETED	RA-4: 13-cis Retinoic Acid for Treatment of Men With Azoospermia
NCT03471455	PHASE2	UNKNOWN	Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis
NCT04154293	PHASE2	COMPLETED	A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis
NCT04594759	PHASE1/PHASE2	COMPLETED	Weekly Isotretinoin Therapy Study
NCT04870489	PHASE2	UNKNOWN	Combined Treatment With CO2 Laser and Isotretinoin for Acne Scars
NCT04909515	PHASE2	WITHDRAWN	Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
NCT05684861	PHASE2	COMPLETED	Serum TWEAK Levels in Acne Vulgaris
NCT01711554	PHASE1	ACTIVE_NOT_RECRUITING	Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
NCT06485505	PHASE1	RECRUITING	Isotretinoin Versus Excimer Light an Adjuvant in Treating Onychomycosis
NCT00000764	PHASE1	COMPLETED	Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.
NCT00005576	PHASE1	COMPLETED	Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma
NCT00014729	PHASE1	COMPLETED	Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa
NCT00070200	PHASE1	COMPLETED	Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma
NCT00098891	PHASE1	COMPLETED	MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
NCT00217412	PHASE1	COMPLETED	Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
NCT00334789	PHASE1	COMPLETED	Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
NCT00416585	PHASE1	COMPLETED	Effects of Roaccutane on Ca, P, PTH and Vitamin D Metabolites in the Treatment of Sever Acne
NCT00867178	PHASE1	COMPLETED	Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
NCT01020539	PHASE1	COMPLETED	Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).